How to Play Gold Po...
Health Care: Drugs
Seattle Genetics Inc. (SGEN: NASDAQ)
$35.73 -0.02 | -0.06%
05/21/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 35.73 |
| 52 Week High | 39.00 |
| 52 Week Low | 19.03 |
| Avg. Daily Vol. (Mil) | 0.80 |
| Beta (3 year) | 1.25 |
| Share Related Items | |
| Mkt Cap (Mil) | 4,332.82 |
| Shares Out (Mil) | 121.27 |
| Float (Mil) | 84.10 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 4.40 |
| Current Ratio | 4.80 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 19.70 |
| Price/Book | 18.57 |
| Price/Cash Flow | -89.40 |
| Per Share Data | |
| Earnings | -0.50 |
| Sales | 1.81 |
| Book Value | 1.92 |
| Cash Flow | -0.40 |
| Business Summary | |
|---|---|
| Seattle Genetics, Inc. is a biotechnology company. It develops and commercializes monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. | |
| General Information | |
| 21823 30th Drive South East
Bothell, WA 98021 |
|
| www.seagen.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 538 | |
| CEO: Dr. Clay B. Siegall,PhD | |
| Short Interest | |
| Current Month (Mil) | 19.08 |
| Previous Month (Mil) | 20.38 |
| Short Interest Ratio (Days) | 21.80 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -12.40 |
| Return on Investments | -24.00 |
| Profitability | |
| Gross Margin | 97.60 |
| EBIT Margin | -26.30 |
| Profit Margin | -26.30 |
Portfolios with SGEN
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorEarnings Short Squeeze Play...
- ProColumbia Wanger Asset Manag...
- ContributorEarnings Short Squeeze Play...
- UserOwn Now
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- ContributorStocks Rising On Unusual Vo...
- Contributor10 Biotech Stocks Loved and...
Latest SGEN Headlines from TheStreet
- 5 Stocks Poised for Breakouts 04.19.13 | 02:04 pm
- Biotech Stock Mailbag: MannKind, Ariad, Oncolytics Biotech 04.05.13 | 07:04 am
- Cramer's Top Stock Picks: QQQ IMGN SGEN ONXX 04.05.13 | 06:04 am
- Declines From Seattle Genetics Inc. (SGEN) Drive Down Health Care Sector 03.28.13 | 05:03 pm
- 4 Stocks Pushing The Drugs Industry Lower 02.13.13 | 12:02 pm
- 5 Stocks Poised to Pop on Bullish Earnings 02.11.13 | 12:02 pm
- Cramer's Top Stock Picks: IMGN ENG SGEN 12.11.12 | 06:12 am
- Cramer's 'Mad Money' Recap: No Deal = No Good 12.10.12 | 08:12 pm
- Celldex Targeted Drug Benefits Patients With Aggressive Breast Cancer 12.10.12 | 07:12 am
- Celldex Targeted Drug Benefits Patients With Aggressive Breast Cancer 12.08.12 | 10:12 am
Press Releases for SGEN
- Seattle Genetics Submits Supplemental BLA To FDA For Retreatment And Extended Duration Of Therapy With ADCETRIS® (Brentuximab Vedotin) In Relapsed Hodgkin Lymphoma And Systemic ALCL - Business Wire 03.18.13 | 09:03 am
- Seattle Genetics To Present At Upcoming Investor Conferences - Business Wire 02.27.13 | 09:02 am
- Seattle Genetics Reports Fourth Quarter And Year 2012 Financial Results - Business Wire 02.12.13 | 04:02 pm
- Seattle Genetics Initiates Two Phase I Trials Of SGN-CD19A - Business Wire 02.06.13 | 09:02 am
- Health Canada Approves ADCETRIS® (Brentuximab Vedotin) For The Treatment Of Relapsed Or Refractory Hodgkin Lymphoma (HL) And Systemic Anaplastic Large Cell Lymphoma (sALCL) - Business Wire 02.01.13 | 02:02 pm
- Seattle Genetics To Host Conference Call And Webcast Discussion Of Fourth Quarter And Year 2012 Financial Results On February 12, 2013 - Business Wire 01.29.13 | 09:01 am
- Seattle Genetics Announces Data From ASG-5ME Phase I Clinical Trial For Pancreatic Cancer - Business Wire 01.25.13 | 09:01 am
- Seattle Genetics And Millennium Initiate Global Phase III Clinical Trial Of ADCETRIS® (Brentuximab Vedotin) In Front-line CD30-Expressing Mature T-Cell Lymphoma (MTCL) - Business Wire 01.24.13 | 09:01 am
- Seattle Genetics To Present At The J.P. Morgan Healthcare Conference - Business Wire 01.03.13 | 09:01 am
- Seattle Genetics Highlights Data Presentations From Genentech ADC Collaborator Programs At ASH Annual Meeting - Business Wire 12.11.12 | 07:12 am
Partner Headlines for SGEN
- Moves in Smaller Health Care Stocks (ANAC, HALO, PBYI, QCOR) - Benzinga 03.23.13 | 11:03 am
- Anything Can Happen This Year For Celldex - Seeking Alpha 02.18.13 | 09:02 am
- Show Me The Money: ADC Revenue Payloads Miss The Mark - Seeking Alpha 11.26.12 | 09:11 am
- UPDATE: Credit Suisse Initiates Seattle Genetics at Outperform; Antubody Pure-Play - Benzinga 11.13.12 | 01:11 pm
- Millennium, Seattle Genetics Announce Phase 3 Clinical Trial of ADCETRIS - Benzinga 11.01.12 | 08:11 am
- Weekly CFO Sells Highlight: SGEN, PFIE, MAR, ESRX, LIOX, RGEN - NASDAQ 09.10.12 | 02:09 pm
- WEEKLY CFO SELLS HIGHLIGHT: SBAC, XOXO, MTH, FICO, SGEN, OAS - NASDAQ 09.03.12 | 02:09 pm
- Armed Antibodies: The Latest Weapon In The War Against Cancer - Seeking Alpha 07.23.12 | 09:07 am
- Healthcare Biz Recap: Affymax On A ROLL, Acadia CRASHES - Wall St. Cheat Sheet 07.15.12 | 11:07 am
- Mid-Cap Biotech Stocks Accumulated By The World's Largest Money Managers - Seeking Alpha 07.13.12 | 06:07 pm
